Sarcoidosis: Difference between revisions
From IDWiki
(Imported from text file) Â |
(→â€)  |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
== |
==Pathophysiology== |
||
* |
*Thought to be related to abnormal T-cell activation |
||
== |
==Differential Diagnosis== |
||
* |
*Hilar lymphadenopathy |
||
** |
**Sarcoidosis |
||
** |
**Infection: TB, fungal, HIV, mycoplasma |
||
** |
**Malignancy: lymphoma |
||
** |
**Others |
||
== |
==Scadding Classification== |
||
# |
#Stage I: Bilateral hilar lymphadenopathy (70% resolve) |
||
# |
#Stage II: Above, with interstitial lung disease (50% resolve) |
||
# |
#Stage III: Interstitial lung disease alone (15% resolve) |
||
# |
#Stage IV: Fibrotic, "burnt out" lungs (0% resolve) |
||
== |
==Risk Factors== |
||
* |
*Women more than men (2:1) |
||
* |
*More common in African-Americans |
||
== |
==Clinical Manifestations== |
||
=== |
===Extrapulmonary disease=== |
||
* |
*Skin: Erythema nodosum and lupus pernio, and others |
||
* |
*Cardiac: 40% of patients, though only 5-10% are symptomatic |
||
* |
*CNS: 5-10%, multiple presentations |
||
* |
*Eyes: 10% of all uveitis cases, usually bilateral |
||
* |
*Hypercalcemia |
||
* |
*Nephrocalcinosis |
||
== |
==Diagnosis== |
||
* |
*Evidence of granulomatous inflammation (often on BAL or EBUS) without infection |
||
* |
*Either lung involvement or multiorgan involvement |
||
== |
==Investigations== |
||
* |
*Labs |
||
** |
**CBC, lytes, creatinine, calcium, liver panel |
||
* |
*Imaging |
||
** |
**High-res CT scan |
||
* |
*Other |
||
** |
**PFTs: most commonly restrictive with decreased DLCO, but can show combined restriction-obstruction, or rarely any other pattern. Often normal. |
||
** |
**EKG for cardiac involvement |
||
** |
**Eye exam for uveitis |
||
== |
==Management== |
||
* |
*Only treat if symptomatic, as many will resolve spontaneously |
||
** |
**Spontaneous remission depends on Scadding stage (I 70%, II 50%, III 15%, IV 0%) |
||
* |
*Prednisone 20-40mg daily for 8-12 weeks, then taper |
||
** |
**Add vitamin D and calcium if serum calcium is low |
||
** |
**Can still use bisphosphates for bone protection |
||
* |
*Second-line steroid-sparing agents include |
||
** |
**Methotrexate |
||
** |
**Azathioprine, leflonamide, MMF, hydroxychloroquine, thalidomide |
||
** |
**TNG-alpha inhibitors are last line |
||
=== |
===Management by organ system=== |
||
{| class="wikitable" |
|||
{| |
|||
! |
!Organ |
||
! |
!Clinical Features |
||
! |
!Treatment |
||
|- |
|- |
||
| |
|Lungs |
||
| |
|Dyspnea w FEV1 or FVC <70% |
||
| |
|Prednisone 24-40 mg/day |
||
|- |
|- |
||
| |
|Lungs |
||
| |
|Cough, wheeze |
||
| |
|Inhaled corticosteroid |
||
|- |
|- |
||
| |
|Eyes |
||
| |
|Anterior uveitis |
||
| |
|Topical corticosteroid |
||
|- |
|- |
||
| |
|Eyes |
||
| |
|Posterior uveitis |
||
| |
|Prednisone 20-40 mg/day |
||
|- |
|- |
||
| |
|Eyes |
||
| |
|Optic neuritis |
||
| |
|Prednisone 20-40 mg/day |
||
|- |
|- |
||
| |
|Skin |
||
| |
|Lupus pernio |
||
| |
|Prednisone 20-40 mg/day<br />Hydroxychloroquine 400 mg/day<br />Thalidomide 100-150 mg/day<br />Methotrexate 10-15 mg/week |
||
|- |
|- |
||
| |
|Skin |
||
| |
|Plaques or nodules |
||
| |
|Prednisone 20-40 mg/day<br />Hydroxychloroquine 400 mg/day |
||
|- |
|- |
||
| |
|Skin |
||
| |
|Erythema nodosum |
||
| |
|NSAID |
||
|- |
|- |
||
| |
|CNS |
||
| |
|Cranial nerve palsies |
||
| |
|Prednisone 20-40 mg/day |
||
|- |
|- |
||
| |
|CNS |
||
| |
|Intracerebral involvement |
||
| |
|Prednisone 40 mg/day<br />Azathioprine 150 mg/day<br />Hydroxychloroquine 400 mg/day |
||
|- |
|- |
||
| |
|Heart |
||
| |
|Complete heart block |
||
| |
|Pacemaker |
||
|- |
|- |
||
| |
|Heart |
||
| |
|Ventricular fibrillation or tachycardia |
||
| |
|AICD |
||
|- |
|- |
||
| |
|Heart |
||
| |
|Decreased LVEF <35% |
||
| |
|AICD and prednisone 30-40 mg/day |
||
|- |
|- |
||
| |
|Liver |
||
| |
|Cholestatic hepatitis with constitutional symptoms |
||
| |
|Prednisone 20-40 mg/day<br />Ursodiol 15 mg/kg per day |
||
|- |
|- |
||
| |
|MSK |
||
| |
|Arthralgias |
||
| |
|NSAID |
||
|- |
|- |
||
| |
|MSK |
||
| |
|Granulomatous arthritis |
||
| |
|Prednisone 20-40 mg/day |
||
|- |
|- |
||
| |
|MSK |
||
| |
|Myositis or myopathy |
||
| |
|Prednisone 20-40 mg/day |
||
|- |
|- |
||
| |
|Calcium |
||
| |
|Kidney stones, fatigue |
||
| |
|Prednisone 20-40 mg/day<br />Hydroxychloroquine 400 mg/day |
||
|} |
|} |
||
from the [NEJM sarcoidosis review article][1] |
from the [NEJM sarcoidosis review article][1] |
||
== |
==Further Reading== |
||
* |
*[1]: Iannuzzi MC, Rubicki BA, and Teirstein AS. [https://doi.org/10.1056/NEJMra071714 Sarcoidosis]. ''N Engl J Med''. 2007 Nov 22;357(21):2153-65. |
||
* |
*Costabel U and Hunninghake GW. [https://erj.ersjournals.com/content/14/4/735.long ATS/ERS/WASOG statement on sarcoidosis]. ''Eur Respir J''. 1999 Oct;14(4):735-7. |
||
[[Category:Rheumatology]] |
[[Category:Rheumatology]] |
Latest revision as of 19:56, 7 September 2020
Pathophysiology
- Thought to be related to abnormal T-cell activation
Differential Diagnosis
- Hilar lymphadenopathy
- Sarcoidosis
- Infection: TB, fungal, HIV, mycoplasma
- Malignancy: lymphoma
- Others
Scadding Classification
- Stage I: Bilateral hilar lymphadenopathy (70% resolve)
- Stage II: Above, with interstitial lung disease (50% resolve)
- Stage III: Interstitial lung disease alone (15% resolve)
- Stage IV: Fibrotic, "burnt out" lungs (0% resolve)
Risk Factors
- Women more than men (2:1)
- More common in African-Americans
Clinical Manifestations
Extrapulmonary disease
- Skin: Erythema nodosum and lupus pernio, and others
- Cardiac: 40% of patients, though only 5-10% are symptomatic
- CNS: 5-10%, multiple presentations
- Eyes: 10% of all uveitis cases, usually bilateral
- Hypercalcemia
- Nephrocalcinosis
Diagnosis
- Evidence of granulomatous inflammation (often on BAL or EBUS) without infection
- Either lung involvement or multiorgan involvement
Investigations
- Labs
- CBC, lytes, creatinine, calcium, liver panel
- Imaging
- High-res CT scan
- Other
- PFTs: most commonly restrictive with decreased DLCO, but can show combined restriction-obstruction, or rarely any other pattern. Often normal.
- EKG for cardiac involvement
- Eye exam for uveitis
Management
- Only treat if symptomatic, as many will resolve spontaneously
- Spontaneous remission depends on Scadding stage (I 70%, II 50%, III 15%, IV 0%)
- Prednisone 20-40mg daily for 8-12 weeks, then taper
- Add vitamin D and calcium if serum calcium is low
- Can still use bisphosphates for bone protection
- Second-line steroid-sparing agents include
- Methotrexate
- Azathioprine, leflonamide, MMF, hydroxychloroquine, thalidomide
- TNG-alpha inhibitors are last line
Management by organ system
Organ | Clinical Features | Treatment |
---|---|---|
Lungs | Dyspnea w FEV1 or FVC <70% | Prednisone 24-40 mg/day |
Lungs | Cough, wheeze | Inhaled corticosteroid |
Eyes | Anterior uveitis | Topical corticosteroid |
Eyes | Posterior uveitis | Prednisone 20-40 mg/day |
Eyes | Optic neuritis | Prednisone 20-40 mg/day |
Skin | Lupus pernio | Prednisone 20-40 mg/day Hydroxychloroquine 400 mg/day Thalidomide 100-150 mg/day Methotrexate 10-15 mg/week |
Skin | Plaques or nodules | Prednisone 20-40 mg/day Hydroxychloroquine 400 mg/day |
Skin | Erythema nodosum | NSAID |
CNS | Cranial nerve palsies | Prednisone 20-40 mg/day |
CNS | Intracerebral involvement | Prednisone 40 mg/day Azathioprine 150 mg/day Hydroxychloroquine 400 mg/day |
Heart | Complete heart block | Pacemaker |
Heart | Ventricular fibrillation or tachycardia | AICD |
Heart | Decreased LVEF <35% | AICD and prednisone 30-40 mg/day |
Liver | Cholestatic hepatitis with constitutional symptoms | Prednisone 20-40 mg/day Ursodiol 15 mg/kg per day |
MSK | Arthralgias | NSAID |
MSK | Granulomatous arthritis | Prednisone 20-40 mg/day |
MSK | Myositis or myopathy | Prednisone 20-40 mg/day |
Calcium | Kidney stones, fatigue | Prednisone 20-40 mg/day Hydroxychloroquine 400 mg/day |
from the [NEJM sarcoidosis review article][1]
Further Reading
- [1]: Iannuzzi MC, Rubicki BA, and Teirstein AS. Sarcoidosis. N Engl J Med. 2007 Nov 22;357(21):2153-65.
- Costabel U and Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Eur Respir J. 1999 Oct;14(4):735-7.